Twitter

Link your Twitter Account to Market Wire News


When you linking your Twitter Account Market Wire News Trending Stocks news and your Portfolio Stocks News will automatically tweet from your Twitter account.


Be alerted of any news about your stocks and see what other stocks are trending.


home / news releases / CNSP - CNS Pharma to discuss IND approval and Phase 2 trial for berubicin today shares up 77%

CNSP - CNS Pharma to discuss IND approval and Phase 2 trial for berubicin today shares up 77%

CNS Pharmaceuticals Inc.
CNS Pharmaceuticals (CNSP) will host a conference call and live webcast today at 8:30 am ET to discuss its Investigational New Drug ((IND)) approval for Berubicin, for the treatment of Glioblastoma Multiforme ((GBM)), and planned Phase 2 Berubicin clinical trial. By the end of the Q1 2021, CNS expects to commence a Phase 2 trial of Berubicin for the treatment of GBM in the U.S., while a sub-licensee partner undertakes a Phase 2 trial in adults and a first-ever Phase 1 trial in pediatric GBM patients in Poland.Yesterday, the FDA signed off CNSP's application for berubicin in brain cancer.Shares up 77% premarket.

For further details see:

CNS Pharma to discuss IND approval and Phase 2 trial for berubicin today, shares up 77%
Stock Information
Company Name: CNS Pharmaceuticals Inc.
Stock Symbol: CNSP
Market: NASDAQ
Website: cnspharma.com
Menu
CNSP CNSP Quote CNSP Short CNSP News CNSP Articles CNSP Message Board
Get CNSP Alerts

News, Short Squeeze, Breakout and More Instantly...